Neurodegeneration

Global Autologous Cell Therapy Market (2022-2027): Emphasis on Drug Development for New Applications Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 22, 2022
Research, Hospitals, Neurology, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Ansoff Matrix, CVD, SWOT, Research, Neurodegeneration, Autoimmune disease, Bone marrow, Porter's five forces analysis, Risk, Growth, Epidermis, Wound healing, Investment, COVID-19, Observation, Market development, Geography, Retail, Risk management, Pharmaceutical industry, Hospital, Cancer

The Global Autologous Cell Therapy Market is segmented based on Source, Applications, End-Users, and Geography.

Key Points: 
  • The Global Autologous Cell Therapy Market is segmented based on Source, Applications, End-Users, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global Autologous Cell Therapy Market.
  • The analyst analyses the Global Autologous Cell Therapy Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Autologous Cell Therapy Market.

Global Pharmaceutical Lipid-based Nanoparticles Research Report 2022: Focus on Pre-clinical and Clinical Advancements - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 22, 2022
Health, Pharmaceutical, Clinical, Cancer, Nutraceutical, Organic acid, Plasmid, Nanomedicine, Traffic barrier, Food, RNA transfection, Research, Neurodegeneration, COVID-19, Cosmetics, Phospholipid, Liposome, Pharmaceutical industry, Lipid, BBB, FDA, Therapy, Brain, Sirna, Nanotechnology, Food and Drug Administration, Vaccine, LNP

The "Lipid-based Nanoparticles for the Pharmaceutical Industry: Pre-clinical and Clinical Advancements" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lipid-based Nanoparticles for the Pharmaceutical Industry: Pre-clinical and Clinical Advancements" report has been added to ResearchAndMarkets.com's offering.
  • This study offers an in-depth analysis of the current research and industrial developments in use of lipid-based nanoparticles.
  • Among the different nanotechnology-based innovations, lipid-based nanoparticles such as liposomes and lipid nanoparticles (LNPs) show great promise across multiple therapies.
  • This research answers the following questions:
    What are the current research advancements in use of LNPs for therapeutic and vaccine delivery?

Worldwide SARM1 Inhibitors Industry to 2040 - Current and Future Market Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, Pharmaceutical, Health, UN, Multiple sclerosis, Death, Sterile alpha motif, Neurodegeneration, Research, Alzheimer's disease, Neurological disorder, Amyotrophic lateral sclerosis, Publication, SARM1, ALS, Patient, Vance DeGeneres, Therapy, First Nations in Ontario, United Nations, Parkinson's disease, Fine chemical, Pharmaceutical industry, Distribution (marketing), Creative industries

This report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of SARM1 inhibitors therapeutics in the healthcare domain, till 2040.

Key Points: 
  • This report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of SARM1 inhibitors therapeutics in the healthcare domain, till 2040.
  • Neurological disorders are considered the second leading cause of death and the primary cause of long-term disability, worldwide.
  • What are the recent developments and strategic initiatives undertaken by players engaged in this market space related to research and development of SARM1 inhibitors therapeutics?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team

Retrieved on: 
Friday, January 6, 2023
Parkinson's disease, Gian Maria Annovi, Toxicology, Chemical process, Laboratory, Pilot plant, Disease, Alzheimer's disease, Forest Products Laboratory, Research, NYSE, Teva Pharmaceuticals, Regulatory Toxicology and Pharmacology, FDA, Cephalon, Process, Neurodegeneration, Pharmaceutical industry, Pharmacology

BERWYN, Penn., Jan. 6, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology.

Key Points: 
  • BERWYN, Penn., Jan. 6, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology.
  • Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis commented, "The expertise of Dr. Michael Christie and David Prohaska will significantly strengthen our ability to conduct successful clinical trials and navigate the regulatory process.
  • Michael Christie, Ph.D., brings to Annovis over 40 years of experience in the pharmaceutical industry.
  • Mr. Prohaska joins Annovis from Aravive Biologics where he served as the Director of Preclinical Development and Clinical Operations Support.

BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023

Retrieved on: 
Thursday, January 5, 2023
Hilton San Francisco Union Square, Biotechnology, Neurodegeneration, Therapy, Pharmaceutical industry, Professional services

NEW YORK, Jan. 5, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Chaim Lebovits, President and CEO, and Stacy Lindborg, Co-CEO, will jointly present a corporate and clinical overview at 10:30 a.m. PT on Monday, Jan. 9 at Biotech Showcase™ 2023 (Hilton San Francisco Union Square, Yosemite A, Ballroom Level).

Key Points: 
  • NEW YORK, Jan. 5, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Chaim Lebovits, President and CEO, and Stacy Lindborg, Co-CEO, will jointly present a corporate and clinical overview at 10:30 a.m. PT on Monday, Jan. 9 at Biotech Showcase™ 2023 (Hilton San Francisco Union Square, Yosemite A, Ballroom Level).
  • Company management will also be available for one-on-one investor meetings at the conference, which can be requested via the Biotech Showcase platform .
  • Those interested in registering for Biotech Showcase may do so using the link, here .

Curebase Celebrates Year of Growth, Organizational Maturity

Retrieved on: 
Wednesday, January 4, 2023
Lviv, Engineering, Patient, Clinical trial, SAN, DCTS, Partnership, Growth, DTA, FDA, Single-frequency network, Neurodegeneration, Publication, VPS, DCT, Gilead Sciences, Software, Physician, RWD, Research, Pharmaceutical industry, Medical device, Management

SAN FRANCISCO, Jan. 4, 2023 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, capped off a successful 2022 with continued growth, maturity, and expansion of its footprint in the decentralized clinical trials (DCT) market.

Key Points: 
  • Curebase was founded in 2017, by CEO Tom Lemberg, to make participation in clinical trials available to any patient, regardless of location.
  • Among the major highlights, accomplishments, and milestones for Curebase in 2022 are:
    The company strengthened its advisory board by naming several industry veterans to the panel.
  • In February, Curebase added Dr. Aaron Kamauu, an industry-leading expert in real-world data (RWD), and Dr. Amir Lahav, an innovator in artificial intelligence/machine learning digital biomarker development for neurodegenerative diseases.
  • At Curebase, our mission is to bring quality medical innovations to patients faster and improve human well-being through more efficient clinical studies.

Wren Builds Out Scientific Advisory Board for Neurodegenerative Diseases

Retrieved on: 
Wednesday, January 4, 2023
Dementia, Medical laboratory, University of Kansas Medical Center, Essential tremor, Neurodegeneration, MIND, University of Nevada, Reno, MTR, School, Achucarro Basque Center for Neuroscience, Drug discovery, Lewy body, Parkinson's disease, Drug development, Neuroinflammation, Science Publishing Group, University, Perelman School of Medicine at the University of Pennsylvania, Doctor of Science, Pathology, Ikerbasque, Therapy, MSA, ALS, Doctor of Philosophy, SAB, Research, Multiple system atrophy, Coronavirus Scientific Advisory Board (Turkey), Movement disorders, Pharmaceutical industry, Medical device, Alzheimer's disease, Neuroscience, Neurology, Wren, MD

BOSTON, Jan. 4, 2023 /PRNewswire/ -- Wren Therapeutics announced today a number of new members to its Scientific Advisory Board.

Key Points: 
  • BOSTON, Jan. 4, 2023 /PRNewswire/ -- Wren Therapeutics announced today a number of new members to its Scientific Advisory Board.
  • "Each of our SAB members brings unrivaled scientific expertise across key areas of neurodegenerative disease biology, preclinical development, and clinical testing that will be invaluable as we advance our first-in-class small-molecule drugs for Parkinson's disease, Alzheimer's disease, and ALS into clinical trials."
  • He has been recognized for this research and leadership contributions in the field of Alzheimer's disease through numerous awards.
  • Her laboratory specializes in the identification and treatment of disease targets in neurodegenerative conditions through translational modeling.

BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer

Retrieved on: 
Wednesday, January 4, 2023
European Medicines Agency, Baylor University, EMA, California Institute for Regenerative Medicine, Badminton Association of India, Amyotrophic lateral sclerosis, Patient, Cell, Food, Commercial, Coronavirus Scientific Advisory Board (Turkey), Biotechnology, Drug development, Heart, COVID-19, FDA, Safety, Neurodegeneration, Doctor of Philosophy, Therapy, Brainstorm, Regenerative medicine, Annual report, Eli Lilly, NTFS, Orphan drug, CIRM, Analytics, Microsoft, Data science, Eli Lilly and Company, Regulation of tobacco by the U.S. Food and Drug Administration, Statistics, MS, ALS Association, Pharmaceutical industry, Management, Biogen, ALS

"I am pleased to announce Stacy's promotion to Co-CEO which is part of a broader strategic initiative to build out our leadership team and position BrainStorm for success," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "Stacy is a strong, collaborative leader who is passionate about transforming the lives of patients through innovation. Her track record in late-stage clinical development and commercial strategy means that she is exceptionally well qualified to guide BrainStorm as we prepare to enter our next phase as a company. I look forward to working with Stacy as we execute on our ultimate goals -- to make NurOwn available to patients and to create value as a commercial organization."  

Key Points: 
  • NEW YORK, Jan. 4, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Stacy Lindborg to the role of Co-Chief Executive Officer.
  • This promotion launches a targeted capability build which will be led by Dr. Lindborg, to hire and bring expertise inside BrainStorm, preparing for success.
  • Stacy Lindborg, Ph.D. joined BrainStorm in 2020 serving most recently as Executive Vice President and Chief Development Officer.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, January 4, 2023
Hebrew University of Jerusalem, CXCR4, Security (finance), Neurodegeneration, Immunotherapy, TASE, Patient, Multiple myeloma, Novartis, Drug development, COVID-19, Medicine, FDA, Bachelor of Medical Sciences, Pancreatic cancer, PDUFA, Psychiatry, PDAC, Therapy, NDA, Cancer, Drug, Annual report, TEL, Risk, Hadassah Medical Center, Pharmaceutical industry, BioLineRx

TEL AVIV, Israel, Jan. 4, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer.  Dr. Rachmilewitz will report to the CEO and lead the Company's clinical and medical functions.  Her appointment is effective today, January 4, 2023.

Key Points: 
  • TEL AVIV, Israel, Jan. 4, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer.
  • "Tami has tremendous experience across a range of therapeutic areas and drug development modalities," said Philip Serlin, Chief Executive Officer of BioLineRx.
  • "I am very excited to be joining a dedicated team focused on bringing best-in-class therapeutics to patients with cancers and to other diseases with significant unmet need," said Tami Rachmilewitz, M.D., Chief Medical Officer at BioLineRx.
  • "I look forward to supporting our clinical and medical teams and working with my fellow leaders at BioLineRx to realize the broad potential of our programs."

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

Retrieved on: 
Tuesday, January 3, 2023
SAN, Drug discovery, Neuropsychiatry, Parkinson's disease, Disease, Movement disorders, ATH, Conference, Neurodegeneration, Multimedia, CNS, ASX, Therapy, Ophthalmology, Alterity, Pharmaceutical industry, Parkinsonism

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF).

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF).
  • The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference.
  • At the conference, Dr. Stamler will be featured on a panel entitled, "New Approaches to Parkinson's and Movement Disorders."
  • Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases.